Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

Tuberculosis (TB) is the world's second leading infectious killer. Cases of multidrug-resistant
(MDR-TB) and extremely drug-resistant (XDR-TB) have increased globally. Therapeutic …

Of all achievements in medicine, the successful treatment of tuberculosis has had one of the
greatest impacts on society. Tuberculosis was a leading cause of disease and a mortal …

This systematic review aimed to update the current evidence for multidrug-resistant
tuberculosis (MDR-TB) treatment. We searched for studies that reported treatment …

Multidrug-resistant (MDR) tuberculosis (TB), resistant to isoniazid and rifampicin, continues
to be one of the most important threats to controlling the TB epidemic. Over the last few …

Tuberculosis (TB) continues to be a significant cause of mortality and morbidity worldwide.
An estimated 2 billion individuals are infected with Mycobacterium tuberculosis and annually …

Despite concerted efforts over the past 2 decades at developing new diagnostics, drugs, and
vaccines with expanding pipelines, tuberculosis remains a global emergency. Several novel …

The emergence of antibiotic resistance in Mycobacterium tuberculosis has been the culprit
behind the inefficient treatment of tuberculosis (TB). Mycobacteriophages being rapid and …

Fluoroquinolones represent the pillar of multidrug-resistant tuberculosis (MDR-TB)
treatment, with moxifloxacin, levofloxacin, or gatifloxacin being prescribed to MDR-TB …

Granulomas are complex lung lesions that are the hallmark of tuberculosis (TB).
Understanding antibiotic dynamics within lung granulomas will be vital to improving and …